Informational Only · Not Medical Advice · Consult a Dermatologist · Editorial Policy

What Is New With Fungal and Acne in October 2026? Latest FDA and dermatology sources and Key Takeaways

In October 2026, prescription-strength adapalene/benzoyl peroxide gel moved over the counter, and oral denifanstat showed sustained 52-week acne control. At the same time, FDA antifungal actions advanced and lab tests targeted Malassezia yeast, the cause of fungal acne, or Malassezia folliculitis.

The practical takeaway is more choice for mild to moderate acne without a prescription visit. Longer-term and lower-cost prescription options are progressing but are not yet routine care. For suspected fungal breakouts, standard acne gels are not proven treatments.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Which acne treatment went over the counter?

Galderma reports in its May approval announcement that FDA approved Differin Epiduo Acne Gel on May 22, 2026 for a prescription-to-OTC switch. The product combines adapalene 0.1% with benzoyl peroxide 2.5% for ages 12 and older.

That change expands nonprescription access to prescription-strength treatment. It matters most for teens and adults with mild to moderate acne who prefer pharmacy access. Check age eligibility and package directions before starting.

What is advancing for stubborn acne?

Dermatology Times reported Sept. 29, 2026 that FDA approved Aleor's generic adapalene gel USP 0.3% for acne vulgaris in patients 12 and older. The report projects about $34M in 12-month market sales, signaling a lower-cost topical retinoid choice. Sagimet reported in its EADV 2026 results summary on Sept. 30, 2026 that oral denifanstat sustained control through 52 weeks in moderate-to-severe acne.

Continuous treatment reached 57.8% success, with no discontinuations for adverse events. Consultant360's EADV recap places those results in an open-label extension in China, not a U.S. approval. Efficacy and safety still need confirmatory review before routine use. Patients should not seek this fatty-acid synthase inhibitor outside a trial.

Do acne gels kill fungal acne yeast?

The Dermatology Digest reported from AAD 2026 that benzoyl peroxide alone and as triple-combination clindamycin/adapalene/benzoyl peroxide inhibited all tested Malassezia strains. Viable M. furfur disappeared within 8 hours in the laboratory report.

The same Dermatology Digest coverage stresses the work was in vitro against cultured folliculitis strains. It does not prove clinical clearance on skin. Readers should not replace prescribed antifungals with acne gels.

What FDA antifungal moves matter this year?

SCYNEXIS said in its January designation notice that FDA granted QIDP and Fast Track on Jan. 21, 2026 for SCY-247. The second-generation triterpenoid targets drug-resistant invasive infections including Candida auris.

The designations bring expedited review and at least 10 years of potential market exclusivity. Separately, Regeneron reported Feb. 24, 2026 that FDA approved Dupixent for allergic fungal rhinosinusitis. The approval covers patients 6 and older with prior sinonasal surgery and cites the 62-patient LIBERTY-AFRS-AIMS trial.

How should you handle benzoyl peroxide now?

FDA testing of 95 benzoyl-peroxide products found more than 90% had undetectable or very low benzene, according to a Drugs.com/GWU summary of FDA alerts. Only six lots faced recall. Keep using effective therapy with simple storage habits:.

  • keep BPO products cool and away from heat
  • discard expired tubes promptly
  • do not abandon working acne treatment from fear alone

You Might Also Like

We use cookies to run this site, measure how it’s used, and show ads. Choose “Essentials only” to limit cookies to what the site needs to work. Privacy Policy.